Objective:To determine medication regularity external therapies of Traditional Chinese medicine of eczema by data mining.Methods:Papers were retrieved from databases Pubmed,CNKI,WF,VIP,CBM,Web of Science and Embase.Fr...Objective:To determine medication regularity external therapies of Traditional Chinese medicine of eczema by data mining.Methods:Papers were retrieved from databases Pubmed,CNKI,WF,VIP,CBM,Web of Science and Embase.From the establishment of the database to April 2020 were searched.The main points of Medication Regularity were established with Excel 2016 software;the characteristics and laws in external therapies of Traditional Chinese medicine Treatment of eczema were analyzed with the relevance rule and cluster analysis Methods in data mining technology.Results:The property and flavor of the herbs mainly used were cold,bitter,while the channel which are mostly involved included liver meridian,lung meridian and Bladder Meridian,The analysis of association rules showed that kushen and difuzi had the highest correlation.The clustering analysis figured out 7groups of the herbs.Conclusion:The study presents the common pair herbs in the treatment of external therapies of Traditional Chinese medicine of eczema,which provides the approach to syndrome differentiation and medication in clinical treatment of eczema.展开更多
Pancreatic neuroendocrine neoplasms(PanNENs)are rare neoplasms with strong heterogeneity that have experienced an increasing incidence rate in recent years.For patients with locally advanced or distant metastatic PanN...Pancreatic neuroendocrine neoplasms(PanNENs)are rare neoplasms with strong heterogeneity that have experienced an increasing incidence rate in recent years.For patients with locally advanced or distant metastatic PanNENs,systemic treatment options vary due to the different differentiations,grades and stages.The available options for systemic therapy include somatostatin analogs,molecularly targeted agents,cytotoxic chemotherapeutic agents,immune checkpoint inhibitors,and peptide receptor radionuclide therapy.In addition,the development of novel molecularly targeted agents is currently in progress.The sequence of selection between different chemotherapy regimens has been of great interest,and resistance to chemotherapeutic agents is the major limitation in their clinical application.Novel agents and high-level clinical evidence continue to emerge in the field of antiangiogenic agents.Peptide receptor radionuclide therapy is increasingly employed for the treatment of advanced neuroendocrine tumors,and greater therapeutic efficacy may be achieved by emerging radiolabeled peptides.Since immune checkpoint inhibitor monotherapies for PanNENs appear to have limited antitumor activity,dual immune checkpoint inhibitor therapies or combinations of antiangiogenic therapies and immune checkpoint inhibitors have been applied in the clinic to improve clinical efficacy.Combining the use of a variety of agents with different mechanisms of action provides new possibilities for clinical treatments.In the future,the study of systemic therapies will continue to focus on the screening of the optimal benefit population and the selection of the best treatment sequence strategy with the aim of truly achieving individualized precise treatment of PanNENs.展开更多
AIM:To investigate the potential role of Active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance. METHODS: In this study, an experimental model was established by hypodermic inoculating the colon can...AIM:To investigate the potential role of Active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance. METHODS: In this study, an experimental model was established by hypodermic inoculating the colon cancer cell line CT26 (5 × 105 cells) into BALB/c mice. The experimental treatment was orally administered with ACML-55 or PBS, followed by the inoculation of colon cancer cell line CT26. Intracellular cytokine staining was used to detect IFN-γ production by tumor antigen specific CD8+ T cells. FACS analysis was employed to profi le composition and activation of CD4+, CD8+, γδ T and NK cells. RESULTS: Our results showed, compared to PBS treated mice, ACML-55 treatment signifi cantly delayed colon cancer development in colon cancer -bearingBalb/c mice in vivo. Treatment with ACML-55 enhanced both Ag specifi c activation and proliferation of CD4+ and CD8+ T cells, and increased the number of tumor Ag specific CD8+ T cells. It was more important to increase the frequency of tumor Ag specific IFN-γ producing-CD8+ T cells. Interestingly, ACML-55 treatment also showed increased cell number of NK, and γδT cells, indicating the role of ACML-55 in activation of innate lymphocytes. CONCLUSION: Our results demonstrate that ACML-55 therapy can enhance function in immune surveillance in colon cancer-bearing mice through regulating both innate and adaptive immune responses.展开更多
基金National key research plan(No.2018YFC1705303)Key research and development plan of Shanxi province(No.2019SF-312).
文摘Objective:To determine medication regularity external therapies of Traditional Chinese medicine of eczema by data mining.Methods:Papers were retrieved from databases Pubmed,CNKI,WF,VIP,CBM,Web of Science and Embase.From the establishment of the database to April 2020 were searched.The main points of Medication Regularity were established with Excel 2016 software;the characteristics and laws in external therapies of Traditional Chinese medicine Treatment of eczema were analyzed with the relevance rule and cluster analysis Methods in data mining technology.Results:The property and flavor of the herbs mainly used were cold,bitter,while the channel which are mostly involved included liver meridian,lung meridian and Bladder Meridian,The analysis of association rules showed that kushen and difuzi had the highest correlation.The clustering analysis figured out 7groups of the herbs.Conclusion:The study presents the common pair herbs in the treatment of external therapies of Traditional Chinese medicine of eczema,which provides the approach to syndrome differentiation and medication in clinical treatment of eczema.
基金Supported by National Key R&D Program of China,No.2019YFB1309704.
文摘Pancreatic neuroendocrine neoplasms(PanNENs)are rare neoplasms with strong heterogeneity that have experienced an increasing incidence rate in recent years.For patients with locally advanced or distant metastatic PanNENs,systemic treatment options vary due to the different differentiations,grades and stages.The available options for systemic therapy include somatostatin analogs,molecularly targeted agents,cytotoxic chemotherapeutic agents,immune checkpoint inhibitors,and peptide receptor radionuclide therapy.In addition,the development of novel molecularly targeted agents is currently in progress.The sequence of selection between different chemotherapy regimens has been of great interest,and resistance to chemotherapeutic agents is the major limitation in their clinical application.Novel agents and high-level clinical evidence continue to emerge in the field of antiangiogenic agents.Peptide receptor radionuclide therapy is increasingly employed for the treatment of advanced neuroendocrine tumors,and greater therapeutic efficacy may be achieved by emerging radiolabeled peptides.Since immune checkpoint inhibitor monotherapies for PanNENs appear to have limited antitumor activity,dual immune checkpoint inhibitor therapies or combinations of antiangiogenic therapies and immune checkpoint inhibitors have been applied in the clinic to improve clinical efficacy.Combining the use of a variety of agents with different mechanisms of action provides new possibilities for clinical treatments.In the future,the study of systemic therapies will continue to focus on the screening of the optimal benefit population and the selection of the best treatment sequence strategy with the aim of truly achieving individualized precise treatment of PanNENs.
基金The National Natural Science Foundation of China,No.30471593 and No. 30670939the Shanghai Leading Academic Discipline Project,No.T0206+1 种基金the Shanghai Commission of Science and Technology,No.07JC14033the Shanghai Institute of Immunology Project,No.07-A02
文摘AIM:To investigate the potential role of Active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance. METHODS: In this study, an experimental model was established by hypodermic inoculating the colon cancer cell line CT26 (5 × 105 cells) into BALB/c mice. The experimental treatment was orally administered with ACML-55 or PBS, followed by the inoculation of colon cancer cell line CT26. Intracellular cytokine staining was used to detect IFN-γ production by tumor antigen specific CD8+ T cells. FACS analysis was employed to profi le composition and activation of CD4+, CD8+, γδ T and NK cells. RESULTS: Our results showed, compared to PBS treated mice, ACML-55 treatment signifi cantly delayed colon cancer development in colon cancer -bearingBalb/c mice in vivo. Treatment with ACML-55 enhanced both Ag specifi c activation and proliferation of CD4+ and CD8+ T cells, and increased the number of tumor Ag specific CD8+ T cells. It was more important to increase the frequency of tumor Ag specific IFN-γ producing-CD8+ T cells. Interestingly, ACML-55 treatment also showed increased cell number of NK, and γδT cells, indicating the role of ACML-55 in activation of innate lymphocytes. CONCLUSION: Our results demonstrate that ACML-55 therapy can enhance function in immune surveillance in colon cancer-bearing mice through regulating both innate and adaptive immune responses.